Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $914,724 | 36 | 99.1% |
| Travel and Lodging | $8,311 | 1 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Rigel Pharmaceuticals, Inc. | $923,035 | 37 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $28,600 | 3 | Rigel Pharmaceuticals, Inc. ($28,600) |
| 2022 | $218,800 | 5 | Rigel Pharmaceuticals, Inc. ($218,800) |
| 2021 | $112,600 | 7 | Rigel Pharmaceuticals, Inc. ($112,600) |
| 2020 | $307,648 | 11 | Rigel Pharmaceuticals, Inc. ($307,648) |
| 2019 | $255,387 | 11 | Rigel Pharmaceuticals, Inc. ($255,387) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/12/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Consulting Fee | Cash or cash equivalent | $15,800.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/12/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 02/02/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Consulting Fee | Cash or cash equivalent | $7,600.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/13/2022 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Consulting Fee | Cash or cash equivalent | $23,400.00 | General |
| Category: Hematology | ||||||
| 09/15/2022 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $52,000.00 | General |
| 08/04/2022 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $70,800.00 | General |
| 04/14/2022 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $35,400.00 | General |
| 03/25/2022 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $37,200.00 | General |
| 10/15/2021 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $11,600.00 | General |
| 10/01/2021 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,600.00 | General |
| 08/05/2021 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $17,400.00 | General |
| 07/02/2021 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $12,000.00 | General |
| 04/28/2021 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $20,400.00 | General |
| 02/11/2021 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $21,400.00 | General |
| 02/04/2021 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $20,200.00 | General |
| 12/17/2020 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $43,000.00 | General |
| 09/10/2020 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $18,400.00 | General |
| 08/06/2020 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $18,800.00 | General |
| 07/02/2020 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $23,600.00 | General |
| 06/05/2020 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $36,000.00 | General |
| 04/21/2020 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $32,848.00 | General |
| 04/21/2020 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $29,000.00 | General |
| 03/11/2020 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $18,200.00 | General |
| 03/05/2020 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $18,200.00 | General |
| 01/30/2020 | Rigel Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $28,200.00 | General |
About Dr. Ann Lowe, M.D
Dr. Ann Lowe, M.D is a Medical Oncology healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2012. The National Provider Identifier (NPI) number assigned to this provider is 1013278811.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ann Lowe, M.D has received a total of $923,035 in payments from pharmaceutical and medical device companies, with $28,600 received in 2023. These payments were reported across 37 transactions from 1 company. The most common payment nature is "Consulting Fee" ($914,724).
Practice Information
- Specialty Medical Oncology
- Location Palo Alto, CA
- Active Since 06/07/2012
- Last Updated 06/07/2012
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1013278811
Products in Payments
- Rezlidhia (Drug) $28,600
- Tavalisse (Drug) $23,400
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Palo Alto
Alice Fan, M.d, M.D
Medical Oncology — Payments: $7,008
Natalia Colocci, Md, MD
Medical Oncology — Payments: $529.87
Dr. Sean Bohen, M.d., Ph.d, M.D., PH.D
Medical Oncology — Payments: $522.21
Dr. Mark Lee, Md, Phd, MD, PHD
Medical Oncology — Payments: $219.83
Paula Kushlan, Md, MD
Medical Oncology — Payments: $129.08
David Leibowitz, Md, MD
Medical Oncology — Payments: $73.41